CHOLESTOSOMES

Serial Number 87158929
606

Registration Progress

Application Filed
Sep 1, 2016
Under Examination
Mar 28, 2017
Approved for Publication
Jan 31, 2017
Published for Opposition
Jan 31, 2017
Registered

Trademark Image

CHOLESTOSOMES

Basic Information

Serial Number
87158929
Filing Date
September 1, 2016
Published for Opposition
January 31, 2017
Abandonment Date
October 29, 2018
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Oct 29, 2018
Classes
005

Rights Holder

TheraHoldings AG

03
Address
Giessenstrasse 41
8835 Feusisberg
CH

Ownership History

TheraHoldings AG

Original Applicant
03
8835 Feusisberg CH

TheraHoldings AG

Owner at Publication
03
8835 Feusisberg CH

Legal Representation

Attorney
R. Neil Sudol

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

23 events
Date Code Type Description Documents
Oct 29, 2018 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Oct 29, 2018 MAB6 O ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED Loading...
Mar 20, 2018 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 16, 2018 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 16, 2018 EXT2 S SOU EXTENSION 2 FILED Loading...
Mar 16, 2018 EX2G S SOU EXTENSION 2 GRANTED Loading...
Sep 5, 2017 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 1, 2017 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 1, 2017 EXT1 S SOU EXTENSION 1 FILED Loading...
Sep 1, 2017 EX1G S SOU EXTENSION 1 GRANTED Loading...
May 1, 2017 DOCK D ASSIGNED TO EXAMINER Loading...
Mar 28, 2017 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jan 31, 2017 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 31, 2017 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jan 11, 2017 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Dec 19, 2016 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 14, 2016 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Dec 14, 2016 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Dec 14, 2016 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Dec 14, 2016 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Dec 10, 2016 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 8, 2016 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Sep 5, 2016 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of any or all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, and cancers of all types, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), ankylosing spondylitis and vaccines and vaccination to prevent or treat infectious diseases and cancer; pharmaceutical preparations, namely, lipid vesicles encapsulating pharmaceuticals for the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of any or all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, and cancers of all types, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), ankylosing spondylitis and vaccines and vaccination to prevent or treat infectious diseases and cancer; pharmaceutical preparations, namely, vesicles made of cholesteryl ester and containing pharmaceuticals for use in the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of any or all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, and cancers of all types, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), ankylosing spondylitis, and vaccines and vaccination to prevent or treat infectious diseases and cancer
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005